Pherecydes Pharma is a pharmaceutical company that engages in the research and development of lytic bacteriophages for therapeutic and diagnostic applications with a focus on antibiotic resistance.
Pherecydes Pharma develops several banks of bacteriophages, including the collection of phages against Escherichia coli.
Pherecydes Pharma was founded in 2006 and is based in Romainville, France.
Pherecydes Pharma is now developping the concept of precision phage therapy, based on the screening of the most effective phages out of a propietary collection of phages to treat each bacterial infection, leading to indivualized treatments.
Pherecydes Pharma owns a vast collection of phages against Escherichia coli (E.coli), Pseudomonas and staphylococcal infections. These three species are responsible for more than 50% of bacterial infections in industrialized countries3.
Pherecydes Pharma's investors include ACE Management, GO CAPITAL, Auriga Partners, & Omnes Capital among others.